27/09/2021 NEW HAVEN, Conn., 27 sept. 2021 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE : BHVN) a annoncé aujourd’hui les résultats d’une analyse ciblée d’un essai clinique sur le verdiperstat dans l’atrophie multisystématisée...
09/27/2021 NEW HAVEN, Conn., 27 set 2021 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) oggi ha annunciato i risultati ottenuti da un’analisi mirata di una sperimentazione clinica di verdiperstat nell’atrofia multisistemica (MSA)....
27/09/2021 NEW HAVEN, Conn., 27 de setembro de 2021 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) anunciou hoje os resultados de uma análise focada de um ensaio clínico de verdiperstat na atrofia do sistema múltiplo (MSA). O...
27/09/2021 NEW HAVEN, Conn., 27 de septiembre de 2021 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) anunció hoy los resultados de un análisis centrado en un ensayo clínico de verdiperstat en la atrofia multisistémica (AMS). El...
VERY DISAPPOINTING NEWS FROM BIOHAVEN RE: VERDIPERSTAT (& M-STAR STUDY)Biohaven remains committed to neuroscience and to the MSA community. They intend to analyze the results further. Biohaven has met with Defeat MSA Alliance all along in this process and informed...
Recent Comments